Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics for approximately $3.9 billion. This acquisition will significa ...

Two months after confirming “advanced talks” for a potential merger, Stamford-based SpringWorks Therapeutics Inc. on Monday ...

The acquisition provides Merck with immediate access to SpringWorks' approved rare cancer therapies - Ogsiveo for aggressive soft tissue tumors and the recently approved Gomekli for nerve sheath ...

After reported discussions since February, German pharma and sciences company Merck KGaA (MRK: DE) has confirmed its ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add ...

This comprehensive summary outlines Australia's Labor government's plan to enhance healthcare with telehealth services, Merck ...

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

U.S. stock futures are little changed as investors ready for a busy earrings calendar, including upcoming reports from Apple, ...

Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire ...

Merck KGaA has announced that it will be acquiring SpringWorks Therapeutics for approximately $3.9bn. The definitive ...

Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash is fair to SpringWorks ...